Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difluprednate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | PGR | P06401 | 7/20 | 0.64 |
| ▸ | AR | P10275 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difluprednate SCHEMBL5486757 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL14339608 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL19961204 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL9954379 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL5486753 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL1276671 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL23343379 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL4581 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL20769772 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL4580 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-12-30 | — | — | US | claimed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | claimed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | claimed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | claimed |
| WO-2016145186-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| US-20110223621-A1 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INC. | 2011-09-15 | — | — | US | claimed |
| US-7915265-B2 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1448205-B1 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2279742-A2 | Combinations for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| US-20100112091-A1 | USE OF RAMOPLANIN TO TREAT DISEASES ASSOCIATED WITH THE USE OF ANTIBIOTICS | NANOTHERAPEUTICS, INC. | 2010-05-06 | — | — | US | claimed |
| US-20070213296-A1 | Compositions and methods for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2007-09-13 | — | — | US | claimed |
| US-7253155-B2 | Combinations for the treatment of immunoinflammatory disorders | COMBINATORX, INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| US-20060234991-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2006-10-19 | — | — | US | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20040072732-A1 | Use of ramoplanin to treat diseases associated with the use of antibiotics | NANOSHIFT, LLC | 2004-04-15 | — | — | US | claimed |
| WO-2003103699-A1 | USE OF RAMOPLANIN TO TREAT DISEASES ASSOCIATED WITH THE USE OF ANTIBIOTICS | VICURON PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2003092617-A2 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | LTA4H, ALOX15B, LTB4R | NR3C1 736/4885HIF1A 1354/4885LMNA 1039/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | NR3C1 32/4885HIF1A 1616/4885LMNA 4264/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | NR3C1 290/4885HIF1A 836/4885LMNA 4018/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | NR3C1 290/4885HIF1A 836/4885LMNA 4018/4885 |
| US-20070213296-A1 | Compositions and methods for the treatment of immunoinflammatory disorders | MPO, IL5, SERPINA6 | NR3C1 252/4885HIF1A 621/4885LMNA 2421/4885 |
| US-20060234991-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, CCL11 | NR3C1 9/4885HIF1A 1820/4885LMNA 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.